Table 1.
Clinicopathological characteristics of 130 patients with BTC.
Fig 1.
Microscopic images showing high- and low-infiltration groups with CD8+, CD4+, FOXP3+, and CD68+ cells. Magnification is 400x, and the scale bar is 25 μm. Immune cells around the tumor are stained brown (arrows). Each patient is classified into the high- or low-infiltration group based on the cutoff value.
Table 2.
Correlation between clinicopathological features and TILs in 130 patients with BTC.
Table 3.
Correlation between clinicopathological features and TAMs in 130 patients with BTC.
Fig 2.
Overall survival and recurrence-free survival for tumor-infiltrating T cells.
Kaplan-Meier survival curve indicates that the high-infiltrating CD4+ TILs group shows significantly superior OS and RFS than the low-infiltrating CD4+ TILs group. The high-infiltrating FOXP3+ TILs group shows significantly superior RFS than the low-infiltrating FOXP3+ TILs group. TILs: tumor-infiltrating lymphocytes, OS: overall survival, RFS: recurrence-free survival, MST: median survival time, N.R.: not reached.
Fig 3.
Overall survival and recurrence-free survival for tumor-associated macrophages.
Kaplan-Meier survival curve indicates that there is no significant difference in OS and RFS between the high- and the low-infiltrating CD68+ TAMs groups. TAMs: tumor-associated macrophages, OS: overall survival, RFS: recurrence-free survival, MST: median survival time.
Table 4.
Univariate and multivariate cox regression analysis for overall survival in 130 patients with BTC.
Table 5.
Univariate and multivariate cox regression analysis for recurrence free survival in 130 patients with BTC.
Fig 4.
Overall survival and recurrence-free survival for tumor-infiltrating immune cells score.
Immunoscore was assigned a number from 0 to 4, according to CD8+ high, CD4+ high, FOXP3+ high, and CD68+ low-infiltration. Kaplan-Meier survival curve indicates that the high Immunoscore group showed significantly superior OS and RFS than the low Immunoscore group. OS: overall survival, RFS: recurrence-free survival, MST: median survival time, N.R.: not reached.
Table 6.
Multivariate cox regression analysis for overall and recurrence free survival in 130 patients with BTC.